Viewpoint
Dr. Meenhard Herlyn
The Wistar Institute, Philadelphia, PA, USA
Abstract: The melanoma landscape is rapidly evolving. The
melanoma oncologists have now the first successful targets for
therapy that have a genetic base – albeit in rare forms of the
malignancy. Once melanoma becomes part of the Cancer Genome
Atlas consortium, a comprehensive map of genetic changes will be
established to point the field to true drivers of the disease that
will become new targets for therapy. The same abnormalities will
also serve as biomarkers for diagnosis, prognosis and therapy
follow-up. Melanomas as a group are heterogenous as are tumor
cells within one lesion. New strategies will move towards
individualized therapies and combination therapies to target all
cells within a tumor.
Driving in the melanoma landscape
Please take time to read this viewpoint from a world renowned Researcher in Cancer
http://www.box.net/shared/kjgr6dkztj
Melanoma and The Magic Bullet (Monoclonal Antibodies)
Take Care,
Jimmy B
No comments:
Post a Comment